Terkeltaub R, Firestein G S, Kornbluth R S, Martin J, Curran D, Manolagas S
Department of Medicine, San Diego VA Medical Center, University of California.
Bone Miner. 1990 Feb;8(2):131-43. doi: 10.1016/0169-6009(90)90116-w.
gamma-Interferon (IFN-gamma) has recently been demonstrated to inhibit the ability of mononuclear phagocytes to degrade bone particles. We have further addressed the specificity, potency and mechanism of this activity using human recombinant IFN-gamma. Adherent peripheral blood mononuclear leukocytes from normal human volunteers were cultured with washed, sieved (less than or equal to 75 microns) 45Ca-labelled rat bone particles for 3 days, after which bone particle degradation (7.1 +/- 1.6%, n = 11) was calculated from the fraction of 45Ca released into the medium. As little as 5 U/ml IFN-gamma significantly suppressed bone particle degradation and 50 U/ml was associated with consistent marked suppression (74.0 +/- 3.5% inhibition, P less than 0.001, n = 11). IFN-gamma was not suppressive if added to cells 24 h or more after exposure to bone particles. Addition of indomethacin (10 microM) did not reverse the effect of IFN-gamma, suggesting that it was not prostaglandin-mediated. In addition, 1,25(OH)2D3 (10 nM) did not remove the inhibitory effect of IFN-gamma. Contact of mononuclear phagocytes with bone particles and secretion of soluble factors from these cells have both been demonstrated to play a role in their ability to degrade bone particles. IFN-gamma (50 U/ml) inhibited monocyte/macrophage interaction with another unopsonized surface, i.e., one micron fluorescent latex particles, decreasing the number of internalized particles from 12.6 +/- 2.9 per cell to 5.9 +/- 1.4 per cell (P less than 0.01, n = 15), as measured using flow cytometry. However, binding of bone particles by the cells was not diminished by IFN-gamma. Exogenous alpha-interferon and human recombinant IL-1 beta, TNF-alpha, and lymphotoxin did not alter bone particle degradation. In addition, endogenous IL-1 beta release from human monocyte/macrophages exposed to bone particles was negligible and unaffected by IFN-gamma. We conclude that IFN-gamma is a potent and specific inhibitor of monocyte/macrophage-mediated bone particle degradation, and that this activity does not appear to be due to effects on the ability of monocytes to bind bone particles or to release IL-1 in response to the particles.
γ-干扰素(IFN-γ)最近已被证明可抑制单核吞噬细胞降解骨颗粒的能力。我们使用重组人IFN-γ进一步研究了这种活性的特异性、效力和机制。将来自正常人类志愿者的贴壁外周血单个核白细胞与洗涤过的、筛过的(≤75微米)45Ca标记的大鼠骨颗粒一起培养3天,之后根据释放到培养基中的45Ca比例计算骨颗粒降解率(7.1±1.6%,n = 11)。低至5 U/ml的IFN-γ即可显著抑制骨颗粒降解,50 U/ml则会持续显著抑制(抑制率为74.0±3.5%,P<0.001,n = 11)。如果在接触骨颗粒24小时或更长时间后将IFN-γ添加到细胞中,则没有抑制作用。添加吲哚美辛(10μM)不能逆转IFN-γ的作用,这表明其作用不是由前列腺素介导的。此外,1,25(OH)2D3(10 nM)不能消除IFN-γ的抑制作用。单核吞噬细胞与骨颗粒的接触以及这些细胞分泌可溶性因子均已被证明在其降解骨颗粒的能力中发挥作用。IFN-γ(50 U/ml)抑制单核细胞/巨噬细胞与另一个未调理的表面(即1微米荧光乳胶颗粒)的相互作用,使用流式细胞术测量,内化颗粒的数量从每个细胞12.6±2.9个减少到5.9±1.4个(P<0.01,n = 15)。然而,IFN-γ不会减少细胞对骨颗粒的结合。外源性α-干扰素以及重组人IL-1β、TNF-α和淋巴毒素不会改变骨颗粒降解。此外,暴露于骨颗粒的人单核细胞/巨噬细胞释放的内源性IL-1β可忽略不计,且不受IFN-γ影响。我们得出结论,IFN-γ是单核细胞/巨噬细胞介导的骨颗粒降解的一种强效且特异性抑制剂,并且这种活性似乎不是由于对单核细胞结合骨颗粒或对颗粒释放IL-1的能力产生影响所致。